SM1
MCID: SCH060
MIFTS: 28

Schistosoma Mansoni Infection, Susceptibility/ (SM1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosoma Mansoni Infection, Susceptibility/

MalaCards integrated aliases for Schistosoma Mansoni Infection, Susceptibility/:

Name: Schistosoma Mansoni Infection, Susceptibility/ 58
Schistosoma Mansoni Infection, Susceptibility/resistance to 58 13
Schistosomiasis 60 74
Sm1 58 17
Schistosoma Mansoni, Intensity of Infection by; Sm1 58
Schistosoma Mansoni, Intensity of Infection by 58
Bilharziasis 60

Characteristics:

Orphanet epidemiological data:

60
schistosomiasis
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
schistosoma mansoni infection, susceptibility/:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare infectious diseases


External Ids:

OMIM 58 181460
MESH via Orphanet 46 D012552
ICD10 via Orphanet 35 B65.0 B65.1 B65.2 more
UMLS via Orphanet 75 C0036323
Orphanet 60 ORPHA1247
MedGen 43 C1866993
SNOMED-CT via HPO 70 263681008
UMLS 74 C0036323

Summaries for Schistosoma Mansoni Infection, Susceptibility/

MalaCards based summary : Schistosoma Mansoni Infection, Susceptibility/, also known as schistosoma mansoni infection, susceptibility/resistance to, is related to schistosomiasis and intestinal schistosomiasis. An important gene associated with Schistosoma Mansoni Infection, Susceptibility/ is SM1 (Schistosoma Mansoni, Susceptibility/Resistance To). The drugs Lidocaine and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include colon, and related phenotype is abnormality of the immune system.

Description from OMIM: 181460

Related Diseases for Schistosoma Mansoni Infection, Susceptibility/

Diseases related to Schistosoma Mansoni Infection, Susceptibility/ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 268)
# Related Disease Score Top Affiliating Genes
1 schistosomiasis 12.9
2 intestinal schistosomiasis 12.8
3 urinary schistosomiasis 12.6
4 cercarial dermatitis 12.1
5 neuroschistosomiasis 11.2
6 hepatic fibrosis, severe due to schistosoma mansoni infection 11.1
7 hepatitis 10.5
8 malaria 10.5
9 bladder cancer 10.4
10 hepatitis c 10.4
11 portal hypertension 10.3
12 fascioliasis 10.3
13 hepatitis b 10.3
14 splenomegaly 10.3
15 filariasis 10.3
16 pulmonary hypertension 10.3
17 appendicitis 10.2
18 parasitic helminthiasis infectious disease 10.2
19 small cell carcinoma 10.2
20 adenocarcinoma 10.2
21 strongyloidiasis 10.2
22 onchocerciasis 10.2
23 filarial elephantiasis 10.2
24 esophageal varix 10.2
25 squamous cell carcinoma 10.2
26 midline interhemispheric variant of holoprosencephaly 10.2
27 hepatocellular carcinoma 10.1
28 pulmonary hypertension, primary, 1 10.1
29 varicose veins 10.1
30 hepatitis c virus 10.1
31 salmonellosis 10.1
32 liver cirrhosis 10.1
33 ectopic pregnancy 10.1
34 ancylostomiasis 10.1
35 myelitis 10.1
36 toxoplasmosis 10.1
37 transverse myelitis 10.1
38 small cell cancer of the lung 10.1
39 lung cancer 10.1
40 neuroblastoma 10.1
41 liver disease 10.0
42 lymphoma 10.0
43 thrombosis 10.0
44 viral hepatitis 10.0
45 paraplegia 10.0
46 leishmaniasis 10.0
47 azoospermia 10.0
48 cysticercosis 10.0
49 trypanosomiasis 10.0
50 nephrotic syndrome 10.0

Graphical network of the top 20 diseases related to Schistosoma Mansoni Infection, Susceptibility/:



Diseases related to Schistosoma Mansoni Infection, Susceptibility/

Symptoms & Phenotypes for Schistosoma Mansoni Infection, Susceptibility/

Human phenotypes related to Schistosoma Mansoni Infection, Susceptibility/:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 33 HP:0002715

Symptoms via clinical synopsis from OMIM:

58
Immunology:
schistosoma mansoni infection susceptibility/resistance

Clinical features from OMIM:

181460

Drugs & Therapeutics for Schistosoma Mansoni Infection, Susceptibility/

Drugs for Schistosoma Mansoni Infection, Susceptibility/ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 71273 175805
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
11
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Anti-Arrhythmia Agents Phase 4
15 Sodium Channel Blockers Phase 4
16 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
17 Anesthetics, Local Phase 4,Phase 3,Phase 2,Not Applicable
18 Diuretics, Potassium Sparing Phase 4
19 Anticonvulsants Phase 4,Phase 3
20 Gastrointestinal Agents Phase 4,Phase 3
21 Analgesics, Non-Narcotic Phase 4
22 glucocorticoids Phase 4
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
24 Tranquilizing Agents Phase 4,Phase 3
25 Anti-Anxiety Agents Phase 4,Phase 3
26 Antineoplastic Agents, Hormonal Phase 4
27 Hormone Antagonists Phase 4
28 Antiemetics Phase 4,Phase 3
29 Analgesics Phase 4,Phase 2,Not Applicable
30 Calcium, Dietary Phase 4
31 Antipyretics Phase 4
32 calcium channel blockers Phase 4
33 Psychotropic Drugs Phase 4,Phase 3
34 Autonomic Agents Phase 4,Phase 3,Phase 2
35 BB 1101 Phase 4
36 Hormones Phase 4
37
protease inhibitors Phase 4
38 Analgesics, Opioid Phase 4
39 Anti-Inflammatory Agents Phase 4
40 HIV Protease Inhibitors Phase 4
41 Narcotics Phase 4
42 Cola Phase 4
43 Anesthetics, Intravenous Phase 4
44 Adjuvants, Anesthesia Phase 4
45 Narcotic Antagonists Phase 4
46 Anesthetics, General Phase 4
47
Oxymetazoline Approved, Investigational Phase 3 1491-59-4 4636
48
Promethazine Approved, Investigational Phase 3,Phase 2 60-87-7 4927
49
Histamine Approved, Investigational Phase 3 51-45-6 774
50
Lorazepam Approved Phase 3,Phase 2 846-49-1 3958

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Volunteers - Part 2 Completed NCT02172729 Phase 4 Adductor canal block with 20 ml lidocaine, single bolus
2 Effect of Paracetamol,Pregabalin and Dexamethasone on Pain and Opioid Requirements in Postoperative Patients Completed NCT00209495 Phase 4 Pregabalin; Dexamethasone
3 Sensory Distribution of Lateral Femoral Cutaneous Nerve Block Completed NCT02957903 Phase 4 Ropivacaine;Isotonic Saline
4 Effect of Adductor-Canal-Blockade on High Pain Responders After Total Knee Arthroplasty Completed NCT01549704 Phase 4 Ropivacaine;Saline
5 Method Study: Bilateral TAP Block With 24 Hours Infusion Completed NCT01577940 Phase 4
6 The Efficacy of Adductor-Canal-Block (ACB) in Patients After Anterior Cruciate Ligament (ACL) Reconstruction Completed NCT01212666 Phase 4
7 The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty Completed NCT01191593 Phase 4
8 Effect of Transversus Abdominis Plane (TAP) Block After Laparoscopic Colon Surgery Completed NCT01418144 Phase 4
9 The Efficacy of Transversus Abdominis Plane Block After Groin Hernia Repair Completed NCT01052285 Phase 4
10 The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy Completed NCT01046071 Phase 4
11 The Efficacy of Adductor-Canal-Blockade on Morphine Consumption, Pain and Mobilisation After Total Knee Arthroplasty Completed NCT01104883 Phase 4
12 Dexamethasone Twice for Pain Treatment of Total Knee Arthroplasty Recruiting NCT03506789 Phase 4 Dexamethasone;Placebos
13 DEXRAR: DEXamethasone in Revision ARthroplasty Recruiting NCT02884180 Phase 4 Dexamethasone;Saline isotonic
14 Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain Suspended NCT00916890 Phase 4 Morphine;Oxycodone;Fentanyl;Buprenorphine
15 Transversus Abdominis Plane Block After Robot-assisted Laparocopic Hysterectomy Terminated NCT01504386 Phase 4
16 An Investigational Study to Assess the Effectiveness and Safety of SM-1 Versus 2 Comparators and Placebo in Participants With a History of Transient Insomnia. Completed NCT03331042 Phase 3 SM-1;D+Z;D+L;Placebo
17 An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia Not yet recruiting NCT03338764 Phase 3 SM-1;Placebo
18 Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia Completed NCT02671760 Phase 2 SM-1;Comparator;Placebo
19 Does Perineural Clonidine Prolong Duration of a Nerve Block? Completed NCT02444559 Phase 2 Ropivacaine 20ml 5mg/ml+ Clonidine 150ug;Ropivacaine 20ml 5mg/ml+ Placebo
20 Impact of Nutrition Labels on Consumer Purchasing Intentions Completed NCT02385838 Not Applicable
21 Pain Map DK: a Prospective Cohort Study of Pain Treatment in 500 Hip Arthroplasty Patients at Different Danish Hospitals Completed NCT02340052 Pain treatment
22 Characterization of Secondary Hyperalgesia in Healthy Volunteers Completed NCT02166164 Not Applicable
23 Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength, Pain and Mobilization After Total Knee Replacement Completed NCT01470391 Not Applicable
24 The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Following Radical Prostatectomy Completed NCT01317368 Not Applicable Naropine;Naropine
25 The Learning Curve of NBI With Magnification in the Diagnosis of Colorectal Lesions Completed NCT01431703
26 Post-endodontic Pain After Single-visit Root Canal Treatment Completed NCT03424655 Not Applicable
27 Cortical Lesions in Patients With Multiple Sclerosis Recruiting NCT03653585
28 Piecemeal Versus En Bloc Resection of Large Rectal Adenomas Recruiting NCT02238938 Not Applicable
29 Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery? Not yet recruiting NCT02885142 Not Applicable

Search NIH Clinical Center for Schistosoma Mansoni Infection, Susceptibility/

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Schistosoma Mansoni Infection, Susceptibility/

Anatomical Context for Schistosoma Mansoni Infection, Susceptibility/

MalaCards organs/tissues related to Schistosoma Mansoni Infection, Susceptibility/:

42
Colon

Publications for Schistosoma Mansoni Infection, Susceptibility/

Variations for Schistosoma Mansoni Infection, Susceptibility/

Expression for Schistosoma Mansoni Infection, Susceptibility/

Search GEO for disease gene expression data for Schistosoma Mansoni Infection, Susceptibility/.

Pathways for Schistosoma Mansoni Infection, Susceptibility/

GO Terms for Schistosoma Mansoni Infection, Susceptibility/

Sources for Schistosoma Mansoni Infection, Susceptibility/

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....